2-(6-chloro-2-pyridyl)propan-2-ol | 40472-97-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(6-chloro-2-pyridyl)propan-2-ol
• 英文别名: 2-(6-Chlor-2-pyridyl)-2-propanol；2-(6-chloro-pyridin-2-yl)-propan-2-ol；2-(6-Chloropyridin-2-yl)propan-2-ol
• CAS: 40472-97-7
• 化学式: C₈H₁₀ClNO
• 分子量: 171.626
• InChiKey: CRJQJYFRDWLMMN-UHFFFAOYSA-N

物化性质

• 沸点：
  252.5±25.0 °C(Predicted)
• 密度：
  1.206±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(6-chloro-2-pyridyl)propan-2-ol 、 1-(4-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]pyrrolidine-3-carboxamide 在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium t-butanolate 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  염증성 질환 치료용 약학적 조성물

  摘要：

  This is the translation of the text you provided: This invention relates to a pharmaceutical composition for the treatment of inflammatory diseases, characterized by a compound represented by the chemical formula I, its pharmaceutically acceptable salts, hydrates, or solvates. According to the present invention, a pharmaceutical composition that interacts with and inhibits the 5-LOX pathway, particularly compounds with inhibitory effects on arachidonate 5-lipoxygenase, can be provided.

  公开号：

  KR101503647B1
• 作为产物：
  描述：

  甲基碘化镁 、 6-氯-2-吡啶羧酸甲酯 以 四氢呋喃 、 乙醚 为溶剂， 反应 3.0h， 生成 2-(6-chloro-2-pyridyl)propan-2-ol
  参考文献：
  名称：

  염증성 질환 치료용 약학적 조성물

  摘要：

  This is the translation of the text you provided: This invention relates to a pharmaceutical composition for the treatment of inflammatory diseases, characterized by a compound represented by the chemical formula I, its pharmaceutically acceptable salts, hydrates, or solvates. According to the present invention, a pharmaceutical composition that interacts with and inhibits the 5-LOX pathway, particularly compounds with inhibitory effects on arachidonate 5-lipoxygenase, can be provided.

  公开号：

  KR101503647B1

文献信息

• [EN] NOVEL SUBSTITUTED INDOLINE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS INDOLINE SUBSTITUTÉS EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE
  申请人：GRUENENTHAL GMBH

  公开号：WO2017108203A1

  公开（公告）日：2017-06-29

  The invention relates to novel compounds characterized in that the compound has general formula (I) in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

  本发明涉及一种新型化合物，其特征在于该化合物具有一般式（I），其中化学基团、取代基、变量和指数如描述中所定义，并且用作药物，特别是用作治疗可以通过抑制PDE4酶来治疗的疾病和病症的药物。
• [EN] ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES
  申请人：ADORX THERAPEUTICS LTD

  公开号：WO2022023772A1

  公开（公告）日：2022-02-03

  The present invention relates to compounds of formula (I) shown below: wherein R1, R2, R3, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a and/or A2b receptor activity is implicated, such as, for example, cancer.

  本发明涉及如下所示的式(I)化合物：其中R1、R2、R3、R4、R5和R6在申请中各自定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗腺苷A2a和/或A2b受体活性参与的疾病或病况中的用途，例如癌症。